33
total announcements
METROPOLIS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹10,900 Cr
P/E (TTM)
54.1
P/E (Forward)
33.9
EPS (TTM)
₹9.71
52W Low
₹412.25
52W High
₹609.05
Dividend Yield
0.37%
Beta
0.20
Price / Book
7.2
Debt / Equity
15.2
Revenue (TTM)
₹1,710 Cr
Gross Margin
77.74%
Operating Margin
17.50%
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about allotment of 9,516 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has provided a business update for Q2FY27, reporting a 15% revenue growth YoY, driven by double-digit patient and test volume growth, improved realizations, and a change in product mix. The company's TruHealth Wellness and Specialty segments emerged as the fastest-growing segments during the quarter. EBITDA margins have improved meaningfully on both YoY and QoQ basis, driven by operating leverage and efficiency gains.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about allotment of 66,312 equity shares under the Metropolis-Restrictive Stock Unit Plan, 2020.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about Other Restructuring, specifically the Share Subscription Agreement and Shareholder's Agreement with Medsource Ozone Biomedicals Private Limited and Dr. Puneet Kumar Nigam for Metropolis Quality Solutions Private Limited, a subsidiary.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about the transcript of Investors & Analyst Meet held on August 27, 2026, where the management team discussed the company's journey, growth, and future plans.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about the link to the recording of the Investors & Analyst Meet held on August 27, 2026.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has transferred its External Quality Assessment Services Business Division to its subsidiary, Metropolis Quality Solutions Private Limited, on a slump sale basis for a consideration of INR 1.25 crore.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about Investor Presentation, which includes information on the company's three-year directional ambitions, revenue mix, and performance.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about disclosure under Regulation 30 of SEBI Listing Regulations regarding the approval of Optionally Convertible Redeemable Preference Shares (OCRPS) issuance by its wholly owned subsidiary, Metropolis Quality Solutions Private Limited. The OCRPS will be issued at par, aggregating to INR 1,00,000/-, and will be converted into equity shares in tranches over up to 6 years.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about meeting with investors scheduled on August 27, 2026.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has submitted the Scrutinizer's Report of the 26th Annual General Meeting held on August 18, 2026, detailing the voting results and compliance with relevant provisions of the Companies Act and Listing Regulations.
Metropolis Healthcare Limited
Metropolis Healthcare Limited held its 26th Annual General Meeting on August 18, 2026, through Video Conferencing. The meeting was attended by 40 shareholders, and the requisite quorum was present. The Chairperson addressed the shareholders, providing an overview of the Company's performance, key achievements, and strategic priorities. Resolutions related to the Audited Financial Statements, Interim Dividends, and director re-appointment were passed.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about the transcript of Q1 FY27 earnings conference call. The company's management discussed the Indian diagnostics industry's structural growth, the shift towards organized quality-led diagnostic providers, and the expanding role of molecular, genomic, and immunological testing.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about the link of recording of the earnings conference call for the quarter ended June 30, 2026.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about the publication of unaudited financial results for the quarter ended June 30, 2026, in 'The Free Press Journal' and 'Navshakti'.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has reported strong Q1FY27 performance with revenue up 17% to ₹450 crore and EBITDA up 27% YoY.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has informed the Exchange about Investor Presentation for the quarter ended June 30, 2026. The presentation highlights the company's revenue growth, EBITDA, and PAT, with a 17% YoY revenue growth, 27% YoY EBITDA growth, and 26% YoY PAT growth. The company has also achieved double-digit patient and test volume growth, with 18% YoY B2C revenue growth and 15% YoY B2B revenue growth.
Metropolis Healthcare Limited
Metropolis Healthcare Limited has submitted its financial results for the quarter ended June 30, 2026, to the NSE and BSE. The company's Board of Directors approved the unaudited standalone and consolidated financial results, which are available on the company's website. The sale and transfer of the company's External Quality Assessment Services Business to a wholly-owned subsidiary is expected to take an additional 2 months.